Drugs / beta interferon
beta interferon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03535298 | Jan 2019 → Jul 2027 expected | relapsing-remitting multiple sclerosis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | beta interferon | “Betaseron (beta interferon)” NCT03535298 ↗ |
| Known as | Avonex (beta interferon) | “Avonex (beta interferon)” NCT03535298 ↗ |
| Known as | Betaseron (beta interferon) | “Betaseron (beta interferon)” NCT03535298 ↗ |
| Known as | Extavia (beta interferon) | “Extavia (beta interferon)” NCT03535298 ↗ |
| Known as | Plegridy (beta interferon) | “Plegridy (beta interferon)” NCT03535298 ↗ |
| Known as | Rebif (beta interferon) | “Rebif (beta interferon)” NCT03535298 ↗ |